Apnimed (NASDAQ:APMD) Trading Down 8.4% – Time to Sell?

Posted by Kim Johansen on Sep 2nd, 2026

Shares of Apnimed, Inc. (NASDAQ:APMD – Get Free Report) were down 8.4% during trading on Monday . The company traded as low as $27.00 and last traded at $27.22. Approximately 131,697 shares were traded during trading, a decline of 65% from the average daily volume of 378,380 shares. The stock had previously closed at $29.71.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on APMD. Bank of America assumed coverage on Apnimed in a research report on Tuesday, August 25th. They issued a “buy” rating and a $41.00 price objective for the company. Zacks Research raised shares of Apnimed to a “hold” rating in a research report on Wednesday, August 26th. Evercore initiated coverage on shares of Apnimed in a research note on Tuesday, August 25th. They set an “outperform” rating for the company. Lifesci Capital initiated coverage on shares of Apnimed in a report on Tuesday, August 25th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Apnimed in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Apnimed has an average rating of “Moderate Buy” and an average price target of $50.33.

Check Out Our Latest Report on Apnimed

Apnimed Stock Performance

Insider Buying and Selling at Apnimed

In other news, major shareholder Morningside Venture Investment acquired 312,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the acquisition, the insider owned 7,152,713 shares of the company’s stock, valued at $114,443,408. This trade represents a 4.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Apnimed Company Profile

(Get Free Report)

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.